Abstract
The addition of the neuropeptide carnosine (beta-alanyl-L-histidine) as a food additive to the basic protocol of Parkinson's disease treatment results in significant improvement of neurological symptoms, along with increase in red blood cell Cu/Zn-SOD and decrease in blood plasma protein carbonyls and lipid hydroperoxides, with no noticeable change in platelets MAO B activity. The combination of carnosine with basic therapy may be a useful way to increase efficiency of PD treatment.
Publication types
-
Controlled Clinical Trial
MeSH terms
-
Adult
-
Aged
-
Carnosine / administration & dosage*
-
Dihydroxyphenylalanine / administration & dosage*
-
Drug Synergism
-
Female
-
Humans
-
Male
-
Middle Aged
-
Monoamine Oxidase / metabolism
-
Oxidative Stress / drug effects
-
Parkinson Disease / drug therapy*
-
Parkinson Disease / metabolism
-
Pilot Projects
-
Protein Carbonylation / drug effects
-
Superoxide Dismutase / metabolism
-
Treatment Outcome
Substances
-
Dihydroxyphenylalanine
-
Carnosine
-
Superoxide Dismutase
-
Monoamine Oxidase